[Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Pheochromocytoma is a very rare tumor that stems from chromaffin cells and usually develops in the adrenal glands. Its equivalent, which exists outside of the adrenal glands, is paraganglioma. Approximately 10-26% of pheochromocytoma is malignant, what poses a significant therapeutical problem, as its presence, together with an abundant production of catecholamines, may lead to a number of perilous complications, such as spinal cord oppression or the damage of organs, what is responsible for producing catecholamines. Due to the risk that the tumor is, it is essential to event new and effective ways of treatment. In case of malignant tumors stemming from chromaffin cells, much is expected from antiangiogenic medicine. Its functioning consists of stopping of the process of neovascularization, which is indispensable for the development of the tumor. Sunitinib - a tyrosine kinase inhibitor - is perhaps the most promising antiangiogenic medicine, whose effectiveness is currently being evaluated in 2nd phase clinical trials. Attempts are also being made to conduct treatment with the use of other medicine of similar functioning, such as: thalidomide, imatinib or evrolimus.
Medical University of Silesia, Katowice, Poland: Department of Internal Medicine and Clinical Pharmacology.
Urszula
U
Kukla
Medical University of Silesia, Katowice, Poland: Department of Internal Medicine and Clinical Pharmacology.
Krzysztof
K
Łabuzek
Medical University of Silesia, Katowice, Poland: Department of Internal Medicine and Clinical Pharmacology.
Justyna
J
Chronowska
Medical University of Silesia, Katowice, Poland: Department of Internal Medicine and Clinical Pharmacology.
Magdalena
M
Bobrzyk
Medical University of Silesia, Katowice, Poland: Department of Endocrinological Gynecology.
PaweŁ
P
Madej
Medical University of Silesia, Katowice, Poland: Department of Internal Medicine and Clinical Pharmacology.
BogusŁaw
B
Okopień
D000310:Adrenal Gland Neoplasms / Q000188:drug therapy*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010235:Paraganglioma / Q000188:drug therapy*; D010673:Pheochromocytoma / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D000077210:Sunitinib; D013792:Thalidomide / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D013792:Thalidomide; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib
angiogenesis; antiangiogenic therapy; paraganglioma; pheochromocytoma; sunitinib